Vor Biopharma Inc. $VOR Shares Acquired by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its holdings in Vor Biopharma Inc. by 218.2% in the first quarter, currently owning approximately 84,945 shares worth $61,000.
• Major shareholder Reprogrammed Interchange LLC sold 447,278 shares of Vor Biopharma, indicating a 1.35% decrease in their ownership position.
• Analysts have issued mixed ratings for Vor Biopharma, with a consensus price target of $113.83 and five analysts rating the stock as a Buy.

Goldman Sachs Group Inc. increased its holdings in Vor Biopharma Inc. (NYSE:VOR - Free Report) by 218.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 84,945 shares of the company's stock after acquiring an additional 58,247 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.07% of Vor Biopharma worth $61,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. OMERS ADMINISTRATION Corp acquired a new position in shares of Vor Biopharma in the first quarter worth about $100,000. Northern Trust Corp lifted its stake in shares of Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after acquiring an additional 44,252 shares in the last quarter. Money Concepts Capital Corp lifted its stake in shares of Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after acquiring an additional 26,535 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Vor Biopharma in the first quarter worth about $140,000. Finally, Two Sigma Investments LP lifted its stake in shares of Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock worth $181,000 after acquiring an additional 25,930 shares in the last quarter. Institutional investors and hedge funds own 97.29% of the company's stock.

Insider Transactions at Vor Biopharma

In related news, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $1.54, for a total value of $688,808.12. Following the completion of the transaction, the insider directly owned 32,781,209 shares of the company's stock, valued at $50,483,061.86. This represents a 1.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders sold 756,918 shares of company stock valued at $12,573,293. Corporate insiders own 0.45% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on VOR. Stifel Nicolaus upgraded Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price objective on the stock in a research note on Wednesday, September 24th. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Finally, HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Vor Biopharma in a research note on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $113.83.

Vor Biopharma Trading Up 22.1%

NYSE:VOR opened at $48.72 on Wednesday. The firm has a market capitalization of $333.93 million, a PE ratio of -29.53 and a beta of 2.05. The stock has a 50 day moving average of $39.19 and a 200-day moving average of $23.76. Vor Biopharma Inc. has a 52 week low of $2.62 and a 52 week high of $65.80.

Vor Biopharma Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.